Clinical trials: Immune Responses
Opioid Withdrawal
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
This Phase 1b/2 inpatient study assessed the safety, pharmacokinetics, and early signs of efficacy of escalating doses of BXCL501 versus placebo following discontinuation of morphine maintenance.
- Trial name
- NCT04470050
- Testing
- Dexmedetomidine
- Where
- 3 sites in United States
- Volunteers
- 225 people
- Sponsor
- BioXcel Therapeutics Inc
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
This randomized, double-blind, parallel-group study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in combination with methotrexate versus RoActemra/Actemra monotherapy in patients with rheumatoid…
- Trial name
- NCT01399697
- Testing
- methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 54 sites in Spain
- Volunteers
- 261 people
- Sponsor
- Hoffmann-La Roche
Infections, Meningococcal
Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine
Meningococcal disease is mostly caused by N. meningitidis of serogroups A, B, C, W-135, Y. Meningococcal polysaccharide-conjugate vaccines have the advantage to induce a T-cell dependant immune response while the existing…
- Trial name
- NCT00356369
- Testing
- meningococcal ACWY (vaccine), Mencevax™ ACWY
- Where
- 3 sites in Philippines, Saudi Arabia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment
The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American…
- Trial name
- FINCH 2 (NCT02873936)
- Testing
- Filgotinib, csDMARDs
- Where
- 104 sites in United States, Argentina and 13 more
- Volunteers
- 449 people
- Sponsor
- Gilead Sciences
Lymphoma
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
This research is being done in order to improve treatment outcomes in patients diagnosed with bulky, early stage Hodgkin lymphoma and to reduce the side effects that are associated with use of radiation used in current…
- Trial name
- NCT01118026
- Testing
- ABVD, BEACOPP, radiation therapy
- Where
- 55 sites in United States
- Volunteers
- 101 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Asthma
Effect of the GSK2245035 on the Allergen-induced Asthmatic Response
This study will assess whether Toll like receptor 7 (TLR7)-mediated pharmacology, with intranasal (i.n.) GSK2245035 20 nanogram (ng) administered weekly for a period of 8 weeks, will lead to reduced allergic reactivity in the…
- Trial name
- NCT02833974
- Testing
- GSK2245035 Nasal Spray Solution
- Where
- 6 sites in Germany, United Kingdom
- Volunteers
- 36 people
- Sponsor
- GlaxoSmithKline
Healthy
A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
The purpose of this study is to compare the body's immune response when vaccines are given alone versus when vaccines are given along with the study drug called ixekizumab. The vaccines protect against pneumonia and tetanus.
- Trial name
- NCT02543918
- Testing
- Ixekizumab, Boostrix®, Pneumovax®23
- Where
- 3 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus
CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS
This study is being done to compare three strategies to deliver HCV treatment with ledipasvir/sofosbuvir which is an approved therapy which is administered as one tablet by mouth daily for 12 weeks.
- Trial name
- CHAMPS (NCT02402218)
- Testing
- Usual care plus peer-mentors, Usual care plus incentives, Usual Care
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Johns Hopkins University
Clostridium Difficile
Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection
Fecal microbiota transplantation (FMT) has been very effective for patients who suffer from mild C diff infection (CDI) which recurs but it is unclear how effective FMT alone is in treating severe and fulminant CDI.
- Trial name
- NCT03760484
- Testing
- Fidaxomicin 200 mg, fecal microbiota transplantation (FMT)
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- University of Alberta
Rheumatoid Arthritis
A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Short Term: The purpose of this clinical research study is to learn if abatacept (BMS-188667) in combination with methotrexate is better than methotrexate alone in participants that have active rheumatoid arthritis and are not…
- Trial name
- NCT00048568
- Testing
- Abatacept, Methotrexate
- Where
- 48 sites in United States
- Volunteers
- 1,250 people
- Sponsor
- Bristol-Myers Squibb
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
This phase III trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed Hodgkin lymphoma.
- Conditions
- Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
- Trial name
- NCT01026220
- Testing
- bleomycin sulfate, doxorubicin hydrochloride, liposomal vincristine sulfate
- Where
- 177 sites in United States, Australia and 3 more
- Volunteers
- 166 people
- Sponsor
- Children's Oncology Group
Asthma, COPD
The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.
This study is a Phase IIa, randomized, placebo-controlled, double-blind, 2-way crossover, 2-center (conducted in EU; The Netherlands) study in male and female subjects with stable, mild HDM-allergic asthma.
- Trial name
- NCT03858686
- Testing
- FP-025 capsules
- Where
- 2 sites in Netherlands
- Volunteers
- 27 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
COVID-19, SARS-CoV-2 Infection
Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
- Trial name
- NECTAR (NCT04924660)
- Testing
- TXA127, TRV027, Fostamatinib
- Where
- 51 sites in United States
- Volunteers
- 1,060 people
- Sponsor
- Sean Collins
Mild Cognitive Impairment, Mild Dementia
A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD
A study of the effects of Bacillus Calmette-Guérin (BCG) immunization on cerebrospinal fluid and blood-based biomarkers in older with mild cognitive impairment and mild-to-moderate to Alzheimer's disease.
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Moderate Dementia, Alzheimer Disease
- Trial name
- NCT05004688
- Testing
- Biological/Vaccine: Bacillus Calmette-Guerin (BCG)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Steven E Arnold, MD
Influenza
Immune Response Following Seasonal Influenza Vaccination
This is an open-label, single administration dose study in adult healthy male and female subjects. After qualifying for the study, subjects will receive a single intramuscular injection of the FDA approved 2016-2017 quadrivalent…
- Trial name
- NCT03163342
- Testing
- Licensed seasonal influenza vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Neoplasms, Pancreatic
First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has been reported to drive pancreatic oncogenesis.
- Trial name
- NCT03681951
- Testing
- GSK3145095, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Graft-Versus-Host Disease
Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids
Background: Sometimes after stem cells are transplanted, donor cells attack the recipient s cells and cause tissue damage. This is called acute graft-versus-host-disease (GVHD).
- Trial name
- NCT02379442
- Testing
- MSC
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Rheumatoid Arthritis
Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA
This study will confirm the ability of Tc 99m tilmanocept imaging to predict clinical response in individuals with RA who are beginning anti-TNFα therapy.
- Trial name
- NCT05246280
- Testing
- TC99m-tilmanocept
- Where
- 13 sites in United States
- Volunteers
- 169 people
- Sponsor
- Navidea Biopharmaceuticals
Influenza
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years…
- Trial name
- NCT00521586
- Testing
- 13 valent pneumococcal conjugate vaccine
- Where
- 41 sites in United States
- Volunteers
- 1,116 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1
Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients
This is a sequential efficacy and safety study in pediatric patients with type 1 diabetes. Subjects will be administered insulin to induce a low normal glycemic state and will then receive an age-appropriate dose of G-Pen…
- Trial name
- NCT03091673
- Testing
- Glucagon
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Xeris Pharmaceuticals